BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 5, 2024
See today's BioWorld
Home
» Hutchison-discovered fruquintinib moves into phase III CRC trial
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Hutchison-discovered fruquintinib moves into phase III CRC trial
Dec. 17, 2014
By
Cornelia Zou
No Comments
HONG KONG – The R&D arm of a China-based health care group owned by the multinational conglomerate Hutchison Whampoa Ltd. (HK:13) has moved its leading oncology candidate into phase III.
BioWorld